Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Liabilities (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Total Liabilities for 7 consecutive years, with $55.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 7.67% to $55.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $55.0 million, a 7.67% increase, with the full-year FY2024 number at $49.8 million, up 55.26% from a year prior.
  • Total Liabilities was $55.0 million for Q3 2025 at 4D Molecular Therapeutics, up from $52.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $55.0 million in Q3 2025 to a low of $14.3 million in Q2 2021.
  • A 5-year average of $33.9 million and a median of $30.5 million in 2022 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: plummeted 85.59% in 2021, then surged 112.9% in 2022.
  • 4D Molecular Therapeutics' Total Liabilities stood at $34.4 million in 2021, then decreased by 11.26% to $30.5 million in 2022, then increased by 5.09% to $32.1 million in 2023, then surged by 55.26% to $49.8 million in 2024, then rose by 10.49% to $55.0 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Total Liabilities are $55.0 million (Q3 2025), $52.7 million (Q2 2025), and $46.0 million (Q1 2025).